<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197805</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00240-53</org_study_id>
    <nct_id>NCT03197805</nct_id>
  </id_info>
  <brief_title>Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients</brief_title>
  <acronym>EQUIVOK</acronym>
  <official_title>Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment Decision-making in Breast Cancer Patients With an ISH Equivocal HER2 Status- EQUIVOK Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NanoString Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The American Society of Clinical Oncology (ASCO) and the /College of American Pathologists
      (CAP) recommend that HER2 status (negative or positive) must be determined in all patients
      with invasive breast cancer. The knowledge of HER2 status will help the oncologist in
      prescribing or not a HER2-targeted therapy to patients. Presently, two main methods are used
      to assess HER2 status: immunohistochemistry (IHC, protein expression) and in situ
      hybridization (ISH, gene expression) in order to classify tumor sample as positive, negative
      or equivocal. When a tumor is classified HER 2+ by IHC method, a second test is performed
      using ISH methods (FISH, SISH, CISH). In case of HER2 equivocal result with ISH method (4
      ≤HER2 gene number copy &lt;6), the patient is eligible to an anti-HER2 therapy after discussed
      during MD-MM. This decision should be individualized on the basis of patient status
      (comorbidities and prognosis) and patient preferences after discussing available clinical
      evidence.

      Based on molecular classification, RNA expression could help to discriminate breast cancer
      subtypes (luminal A, luminal B, HER2-overexpressed and triple negative). Prosigna is a
      genomic test, developed by NanoString® based on the PAM50 gene signature, which measures the
      expression of 50 genes to classify tumors into 1 of 4 intrinsic subtypes and could allow
      determining the HER2 status.

      This study was designed in order to define if such a test could help the oncologist to define
      the better therapeutic decision in a HER2 equivocal population. In addition, concordance
      tests will be performed. The aim of this study is to assess the modification decision rate
      between the first and the second multidisciplinary decision-making meeting in HER2 equivocal
      patients using genomic testing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort longitudinal follow up</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The modification of therapeutical decision between the first and the second multidisciplinary decision-making meeting (MD-MM) using a genomic testing</measure>
    <time_frame>The measure will be realised after the second multidisciplinary decision-making meeting that is about one month after patient's inclusion.</time_frame>
    <description>Percentage of therapeutical strategy changes between the first and the second multidisciplinary decision-making meetings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The HER2 overexpression incidence according to RNA genomic profile among equivocal-HER2 patients</measure>
    <time_frame>The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion.</time_frame>
    <description>Percentage of HER2 classified patients using a genomic test among equivocal-HER2 patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance between the second multidisciplinary decision-making meeting decision and the HER2 genomic test result</measure>
    <time_frame>The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion.</time_frame>
    <description>Percentage of second multidisciplinary decision-making meeting decision in accordance with genomic test result and reasons justifying discrepancies (check-list and comments)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To compare results from different ISH methods used</measure>
    <time_frame>The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion..</time_frame>
    <description>Comparison between all ISH (FISH, SISH, CISH, or DDISH) methods based upon the HER2-eligible classification (Wolff et al 2013)</description>
  </other_outcome>
  <other_outcome>
    <measure>The concordance between local and centralized anatomopathologist HER2 status</measure>
    <time_frame>The measure will be done when the genomic test is realised,that is about three weeks after patient's inclusion.</time_frame>
    <description>Concordance between local and centralized anatomopathologist HER2 status.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Use of PAM 50 test in Her2 equivocal breast cancer patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio &lt;2 and 4 ≤HER2 gene number copy &lt; 6) will be eligible for RNA genomic test (PAM 50 test).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PAM 50 test</intervention_name>
    <description>Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio &lt;2 and 4 ≤HER2 gene number copy &lt; 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.</description>
    <arm_group_label>Use of PAM 50 test in Her2 equivocal breast cancer patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status ≤ 2 (according to WHO criteria)

          -  Patient with early invasive breast cancer histologically confirmed stage I to IIIA)

          -  Positive or negative lymph node involvement

          -  Positive or negative Hormonal Receptors (Estrogens and/or Progesterone),

          -  Equivocal HER2 status (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio &lt;2
             and 4 ≤ HER2 gene number copy &lt; 6) as assessed on surgical specimen

          -  Adequate Hematological, Hepatic, Renal and Cardiac Functions

          -  Patient potentially eligible for an anti-HER2 therapy

          -  Patient eligible to receive an adjuvant therapy

          -  Signed Informed Consent

          -  Patient with social insurance.

        Exclusion Criteria:

          -  Non-measurable tumor

          -  Unknown Hormonal Receptors

          -  Unknown node involvement

          -  Positive or negative HER2 status (Score 0, 1 or 3 IHC, or Negative or positive ISH)

          -  Disease stage ≥IIIB

          -  Patient not able to follow the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Ange MOURET-REYNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine ABRIAL, PhD</last_name>
    <phone>04 73 27 84 91</phone>
    <email>catherine.abrial@clermont.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie REYMOND</last_name>
    <phone>04 73 27 80 05</phone>
    <email>Marie.REYMOND@clermont.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Jean Minoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine BARGOT-GUGLIELMETTI</last_name>
      <email>c1guglielmetti@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier PIVOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie ARDILOUZE</last_name>
      <email>L.Ardilouze@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie QUENEL-TUEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine ABRIAL, PhD</last_name>
      <phone>33473278491</phone>
      <email>catherine.abrial@clermont.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie REYMOND</last_name>
      <email>marie.reymond@clermont.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine TIAGO</last_name>
      <email>stiago@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Françoise BELTJENS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michalon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine RAMOND</last_name>
      <email>ARamond@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé CURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda PERVIEUX</last_name>
      <email>Lynda.Pervieux@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence VENAT BOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle FLORENT</last_name>
      <email>christelle.florent@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecile LUBRANO-BERTHELIER</last_name>
      <email>BERTHELIERC@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Carole TARPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine MEUNIER</last_name>
      <email>Sandrine.MEUNIER@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aude-Marie SAVOYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer COURLANCY</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie HEIL</last_name>
      <email>NHEIL@iccreims.fr</email>
    </contact>
    <investigator>
      <last_name>David COEFFIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise SISTAC</last_name>
      <email>Francoise.Sistac@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-sébastien FRENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam ESTRABAUT</last_name>
      <email>Estrabaut.Myriam@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Dalenc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Equivocal Her 2</keyword>
  <keyword>Genomic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

